A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, October 2009

Altmetric Badge

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 38 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Ixekizumab for treating moderate to severe plaque psoriasis: Committee papers

Cited by National Institute for Health and Care Excellence on 25 Oct 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.